five

A Phase 3b Multicenter, Single-Blind Trial to Evaluate the Efficacy of Dexlansoprazole MR 30 mg in Maintaining Control of Gastroesophageal Reflux Disease Symptoms in Subjects on Prior Twice Daily Proton Pump Inhibitor Therapy

收藏
DataCite Commons2025-04-01 更新2026-05-07 收录
下载链接:
https://search.vivli.org/doiLanding/studies/00002508/isLanding
下载链接
链接失效反馈
官方服务:
资源简介:
The purpose of this study is to determine if patients with well-controlled heartburn symptoms on twice-daily proton pump inhibitor therapy remain well-controlled after stepping down to once-daily (QD) dexlansoprazole modified release (MR) 30 mg.
提供机构:
Vivli
创建时间:
2018-10-27
二维码
社区交流群
二维码
科研交流群
商业服务